Changes and clinical significance of SCC,ProGRP and CEA levels in patients with non-small cell lung cancer
Objective To investigate the changes and clinical significance of squamous cell carci-noma-associated antigen(SCC),pro-gastrin releasing peptide(ProGRP)and carcinoembryonic antigen(CEA)levels in patients with non-small cell lung cancer(NSCLC).Methods A retrospective analysis was conducted on the clinical data of 132 patients with NSCLC who were treated at Beijing Friendship Hospital Af-filiated to Capital Medical University from May 2020 to February 2023.The patients were divided into group A,while 71 patients with benign pulmonary lesions were selected and placed in group B simultaneously.The levels of SCC,ProGRP and CEA were compared between the two groups,and further analysis was done on the levels of SCC,ProGRP and CEA in NSCLC patients with different clinical characteristics.The receiver op-erating characteristic(ROC)curves were used to evaluate the diagnostic value of SCC,ProGRP,and CEA in NSCLC.Results Serum SCC,ProGRP,and CEA levels in group A were higher than those in group B(P<0.05).The AUC values for serum SCC,ProGRP,CEA and their combination in diagnosing NSCLC were 0.691,0.815,0.822 and 0.832,respectively.There were statistically significant differences in serum SCC,ProGRP and CEA levels among NSCLC patients with different pathological types,different degrees of differ-entiation,various clinical stages,and with or without lymph node metastasis(P<0.05).Conclusion Patients with different pathological types,varying degrees of differentiation,diverse clinical stages,and presence or absence of lymph node metastasis exhibit varying levels of serum SCC,ProGRP and CEA.These biomarkers can significantly aid in the diagnosis of NSCLC,with a combination of all three leading to enhanced diagnostic accuracy.
NETL
NSTL
万方数据
